课题基金 / 基金详情

KLF14 and Cardiovascular Disease

KLF14 and Cardiovascular Disease
KLF14 与心血管疾病
批准号:
10319617
负责人:
YUQING Eugene CHEN
金额:
$61.86万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-04-01 至 2025-02-28

项目摘要

项目成果

YUQING Eugene CHEN的其他基金

相似基金

相关文献

中文摘要
翻译
腹主动脉瘤(Aaa)是一种无症状的疾病,如果破裂,死亡率很高(65%~85%)。 发生。手术修复是唯一有效的治疗方法,但仅限于符合条件的患者(约占总数的10%)。不是 已发现有效的药理学方法来限制AAA的进展和破裂。男性性行为是一种 AAA的重要危险因素,男女患病率比约为4-6:1。发生这种性行为的原因 差异尚不清楚,但女性AAA的延迟发病表明雌激素及其受体(ER) 可能在降低AAA患病率方面发挥作用。雌激素对腹主动脉瘤的保护作用 通过减少促炎介质和蛋白分解途径建立动物模型。然而,龙- 长期雌激素治疗由于不良副作用,不能广泛应用于AAA患者的治疗。人类 遗传学研究发现Kruppel-like factor14(KLF14)与慢性代谢密切相关 有性别差异的疾病。我们先前报道了KLF14及其激活剂的生物学功能, 培己胺,临床上用于治疗心绞痛和心力衰竭,在脂代谢方面表现出较强的 KLF14的抗炎作用。我们在这里描述的初步数据确定了巨噬细胞- 选择性KLF14基因敲除小鼠显示雌性AAA发病率显著增加,与 提示雌激素/ERα/β途径的保护作用受损。除了抑制之外 KLF14对炎症反应和基质金属蛋白酶-9活性的影响,进一步发现雌激素上调 KLF14的表达,而KLF14又是一个关键的转录因子,上调了 巨噬细胞中的ERα/β,揭示了一个前馈环路,这可能有助于观察到的性别差异。 培氟西林以KLF14依赖的方式增加ERα/β水平。一种胆固醇代谢产物,24- 羟基胆固醇(24HC)作为内源性ER-α/β激动型分子发挥作用,增强内源性ER-TdR活性。 培己胺对巨噬细胞的炎症作用。最重要的是,培己胺的使用显著 减少AAA的分离/破裂,提高雄性小鼠的存活率。根据我们的初步发现, 拟议的项目将检验KLF14预防AAA发展/夹层的中心假设 通过抑制炎症和增强巨噬细胞中ER-α/β依赖的保护作用来抑制/破裂。这个 特定的目的将1)确定巨噬细胞KLF14是AAA小鼠性别差异的重要调节因素 模型;2)确定KLF14如何调节导致性二型性的雌激素/雌激素受体途径 对AAA的保护作用;以及3)确定KLF14的激活抑制了脑发育/夹层/破裂。 AAA小鼠模型。基于KLF14在AAA中的性别特异性功能,这一机制研究将 将KLF14作为新的治疗靶点,将为临床应用奠定坚实的基础 KLF14激活剂,如培己胺,作为治疗AAA的可行药物,具有改变电流的潜力 腹主动脉瘤的治疗范例。
英文摘要
Abdominal aortic aneurysm (AAA) is an asymptomatic disease of high mortality rate (65% to 85%) if rupture occurs. Surgical repair is the only effective treatment, but limited to eligible patients (about 10% of total). No effective pharmacological approach has been identified to limit AAA progression and rupture. Male sex is an important risk factor for AAA, with about 4-6:1 male to female prevalence ratio. The reasons for this sex disparity are unknown, but the delayed onset of AAA in women suggests that estrogen and its receptors (ERs) may play a role in reducing the prevalence of AAA. Administration of estrogen has protective effects in AAA animal models through reduction of pro-inflammatory mediators and the proteolytic pathway. However, long- term estrogen therapy cannot be widely applied to treat AAA patients due to undesirable side-effects. Human genetic studies uncovered that Kruppel-like factor 14 (KLF14) is robustly associated with chronic metabolic diseases with a sex difference. We previously reported the biological function of KLF14 and its activator, perhexiline, clinically used to treat angina and heart failure, in lipid metabolism and demonstrate the strong anti-inflammatory effect of KLF14. Our preliminary data described herein established that macrophage- selective Klf14 knockout mice showed significantly increased AAA incidence rates in females, comparable to those in males, suggesting impaired protective effects of estrogen/ERα/β pathway. Besides the inhibitory effects of KLF14 on the inflammatory response and MMP-9 activity, we further found that estrogen upregulates the expression of KLF14 while KLF14, in turn, is a critical transcription factor upregulating the expression of ERα/β in macrophages, uncovering a feedforward loop that may contribute to the observed sex disparity. Perhexiline increased the levels of ERα/β in a KLF14-dependent manner. A cholesterol metabolite, 24- hydroxycholesterol (24HC), functioned as an endogenous ERα/β agonistic molecule and enhanced the anti- inflammatory effect of perhexiline in macrophages. Most importantly, administration of perhexiline significantly reduced AAA dissection/rupture and increased survival rate in male mice. Based on our preliminary findings, the proposed project will test the central hypothesis that KLF14 protects against AAA development/dissection /rupture by suppressing inflammation and enhancing ERα/β-dependent protective roles in macrophages. The specific aims will 1) define that macrophage KLF14 is an important regulator of sex differences in AAA mouse models; 2) determine how KLF14 regulates the estrogen/ERs pathway which contributes to sex-dimorphic protective effects on AAA; and 3) determine that activation of KLF14 inhibits development/dissection/rupture in AAA mouse models. Based on the sex-specific functions of KLF14 in AAA, this mechanistic research will establish KLF14 as a novel therapeutic target and will set a solid foundation towards clinical utilization of KLF14 activators, like perhexiline, as a viable drug therapy for AAA, with the potential to change current treatment paradigms for AAA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nitro-Fatty Acids and Cardiovascular Disease
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
Development of gene editing based therapy for cardiovascular diseases
海外基金